Proton Pompası İnhibitörleri için Omeprazol Sentezi

Kiral selektif kimyayla mide asidini kontrol etme

Pharmaceutical & Drug Manufacturing Global Industrial Scale $3.5 billion

Genel Bakış

Omeprazole is the first proton pump inhibitor (PPI) to reach the market and remains one of the most prescribed medications globally for treating gastric acid disorders, peptic ulcers, and GERD. The synthesis involves a multi-step process building the benzimidazole-pyridine core structure. The chiral version, esomeprazole (the S-enantiomer), represents a significant pharmaceutical advancement, produced using an asymmetric oxidation that won AstraZeneca substantial patent protection.

Kimyasal Süreç

2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.

Thioether intermediate + m-CPBA → Omeprazole (sulfoxide)
For esomeprazole: Ti(OiPr)₄/(R,R)-DET/cumene hydroperoxide → S-omeprazole (>99.5% ee)

Hammaddeler

  • 5-Methoxy-2-mercaptobenzimidazole — Multi-step synthesis from o-phenylenediamine (Core structure)
  • 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine — Pyridine chemistry (Pyridine moiety)
  • m-CPBA (meta-chloroperoxybenzoic acid) — Chemical synthesis (Oxidizing agent)

Son Ürünler

  • Omeprazole (C₁₇H₁₉N₃O₃S) — Proton pump inhibitor for GERD and ulcers (Racemic or enantiopure form)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.

Güvenlik Hususları

Son İnovasyonlar

Biocatalytic oxidation using engineered cytochrome P450 enzymes and Baeyer-Villiger monooxygenases offers enantioselective sulfoxidation under mild conditions, potentially replacing chemical oxidants entirely.

Üretim Ölçeği

800

ton/yıl

$3.5 billion

Piyasa değeri

Daha fazlası Pharmaceutical & Drug Manufacturing

Amoksisilin Yarı-Sentetik Üretimi

Global Industrial Scale

Fermantasyonla Penisilin G Üretimi

Global Industrial Scale

İbuprofen Sentezi — BHC Yeşil Süreci

Global Industrial Scale

Metformin Hidroklorür Sentezi

Global Industrial Scale

Parasetamol (Asetaminofen) Sentezi

Global Industrial Scale

Rekombinant İnsan İnsülini Üretimi

Global Industrial Scale

Salisilik Asidin Asetilasyonuyla Aspirin Sentezi

Global Industrial Scale

Frequently Asked Questions

What industry uses Proton Pompası İnhibitörleri için Omeprazol Sentezi?
Proton Pompası İnhibitörleri için Omeprazol Sentezi is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in Proton Pompası İnhibitörleri için Omeprazol Sentezi?
2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.
What is the economic significance of Proton Pompası İnhibitörleri için Omeprazol Sentezi?
Proton Pompası İnhibitörleri için Omeprazol Sentezi has a market value of $3.5 billion and annual production of 800 tons.
What is the environmental impact of Proton Pompası İnhibitörleri için Omeprazol Sentezi?
Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.
What raw materials are used in Proton Pompası İnhibitörleri için Omeprazol Sentezi?
The main raw materials include: 5-Methoxy-2-mercaptobenzimidazole, 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine, m-CPBA (meta-chloroperoxybenzoic acid).